Subscribe to RSS
Download PDF
DOI: 10.1055/s-0040-1712067
Pediatric Non–Brain Stem High-Grade Glioma: A Single-Center Experience
Authors
Funding None.
Abstract
Background Pediatric high-grade gliomas (PHGGs) consist of a heterogeneous class of central nervous system (CNS) neoplasms with a poor prognosis. We aimed to present our 10-year experience in the management of children with high-grade glioma focusing on patients’ survival and related factors.
Methods All pediatric patients with high- grade glioma (HGG) who were admitted to our center between May 2009 and May 2018 were investigated. Overall survival (OS) was calculated from the time of diagnosis until the day of death. The impact of suggested variables on survival was evaluated using the univariate and multivariate analyses.
Results There were 41 children with non–brain stem high-grade glioma (NBSHGG). The mean OS of patients was 21.24 ± 10.16 months. The extent of resection (p = 0.002, hazard ratio [HR] = 4.84), the grade of the tumor (p = 0.017, HR = 4.36), and temozolomide (TMZ) therapy (p = 0.038, HR = 3.57) were the independent predictors of OS in children with NBSHGG. Age, gender, tumor location, and size of tumor were not associated with the survival of these patients.
Conclusion HGGs are uncommon pediatric tumors with an aggressive nature and a poor prognosis. Our results revealed that in NBSHGG cases, children with maximal safe tumor resection and children that received temozolomide therapy as well as children with grade III of the tumor had higher survival.
Publication History
Article published online:
12 June 2020
© 2020. Neurological Surgeons’ Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Adams H, Adams HH, Jackson C, Rincon-Torroella J, Jallo GI, Quiñones-Hinojosa A. Evaluating extent of resection in pediatric glioblastoma: a multiple propensity score-adjusted population-based analysis. Childs Nerv Syst 2016; 32 (03) 493-503
- 2 Blionas A, Giakoumettis D, Klonou A, Neromyliotis E, Karydakis P, Themistocleous MS. Paediatric gliomas: diagnosis, molecular biology and management. Ann Transl Med 2018; 6 (12) 251
- 3 Bradley WG. Achieving gross total resection of brain tumors: intraoperative MR imaging can make a big difference. AJNR Am J Neuroradiol 2002; 23 (03) 348-349
- 4 Broniscer A. Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest 2006; 24 (01) 77-81
- 5 Mak KS, Lee SW, Balboni TA, Marcus KJ. Clinical outcomes and toxicity following palliative radiotherapy for childhood cancers. Pediatr Blood Cancer 2018;65(1)
- 6 Nikitović M, Stanić D, Pekmezović T. et al. Pediatric glioblastoma: a single institution experience. Childs Nerv Syst 2016; 32 (01) 97-103
- 7 Lam S, Lin Y, Zinn P, Su J, Pan I-W. Patient and treatment factors associated with survival among pediatric glioblastoma patients: a surveillance, epidemiology, and end results study. J Clin Neurosci 2018; 47: 285-293
- 8 Perkins SM, Rubin JB, Leonard JR. et al. Glioblastoma in children: a single-institution experience. Int J Radiat Oncol Biol Phys 2011; 80 (04) 1117-1121
- 9 Yang T, Temkin N, Barber J. et al. Gross total resection correlates with long-term survival in pediatric patients with glioblastoma. World Neurosurg 2013; 79 (3-4) 537-544
- 10 Eisenstat DD, Pollack IF, Demers A. et al. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children’s Cancer Group high-grade glioma study CCG-945. J Neurooncol 2015; 121 (03) 573-581
- 11 Song KS, Phi JH, Cho BK. et al. Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr 2010; 6 (02) 145-149
- 12 Perkins SM, Rubin JB, Leonard JR. et al. Glioblastoma in children: a single-institution experience. Int J Radiat Oncol Biol Phys 2011; 80 (04) 1117-1121
- 13 Fangusaro J. Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol 2012; 2: 105
- 14 Jones C, Karajannis MA, Jones DTW. et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-oncol 2017; 19 (02) 153-161
- 15 Das KK, Mehrotra A, Nair AP. et al. Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome. Childs Nerv Syst 2012; 28 (12) 2055-2062
- 16 Ehrstedt C, Kristiansen I, Ahlsten G. et al. Clinical characteristics and late effects in CNS tumours of childhood: do not forget long term follow-up of the low grade tumours. Eur J Paediatr Neurol 2016; 20 (04) 580-587
- 17 Muhammed A, Gaber MS, Elbeltagy M. et al. Risk stratification of pediatric high-grade glioma: a newly proposed prognostic score. Childs Nerv Syst 2019; 35 (12) 2355-2362
- 18 Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 2004; 9 (02) 197-206
- 19 Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical—and futuristic—perspective. J Neurooncol 2005; 75 (03) 253-266
- 20 Das KK, Mehrotra A, Nair AP. et al. Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome. Childs Nerv Syst 2012; 28 (12) 2055-2062
- 21 Koschmann C, Zamler D, MacKay A. et al. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget 2016; 7 (40) 65696-65706
- 22 Uppar AM, Sugur H, Prabhuraj AR. et al. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance. Childs Nerv Syst 2019; 35 (09) 1537-1545
- 23 Stupp R, Mason WP, van den Bent MJ. et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; , National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
- 24 Cohen KJ, Pollack IF, Zhou T. et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro-oncol 2011; 13 (03) 317-323
- 25 Jakacki RI, Cohen KJ, Buxton A. et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study. Neuro-oncol 2016; 18 (10) 1442-1450